Trial Profile
A Randomized, Open-Label Trial to Compare the Efficacy, Safety and Tolerability of DRV/Rtv [darunavir + ritonavir] (800mg/100mg) q.d Versus DRV/Rtv (600mg/100mg) b.i.d in Early Treatment-Experienced HIV-1 Infected Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Ritonavir (Primary)
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms ODIN
- Sponsors Janssen R&D Ireland
- 25 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 16 Nov 2017 Results summarizing the development (or identification) of post-baseline resistance (RAMs and antiretroviral phenotypic susceptibility) among subjects receiving darunavir QD dosing published in the HIV Clinical Trials
- 16 Feb 2017 Results (n=2329) of seven phase 2 and 3 studies (ARTEMIS, GS-US-299-0102, ODIN, MONET,PROTEA, GS-US-216-0130,INROADS ) presented at the 24th Conference on Retroviruses and Opportunistic Infections.